David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.
David Sommerhalder, MD
Advertisement
Articles by David Sommerhalder, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
2
Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer
3
Dr Encinas Mayoral on an AI-Designed BCMA/FcRL5-Targeting TRiTE in Multiple Myeloma
4
Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC
5